


**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the present application.

1. (currently amended) A compound according to formula (I)



(I)

wherein

$\text{X}^1$  is  $(\text{HO})_2\text{PO}-\text{Z}^1-$ ;

$\text{X}^2$  and  $\text{X}^3$  are both  $\text{R}^1\text{R}^2\text{N}-$  with each being the same or different;

$\text{Z}^1$  is  $-\text{O}(\text{CH}_2)_m-$  with  $m$  being an integer from 1 to 50, or  $-\text{O}-$ ;

$\text{Q}^1$  and  $\text{Q}^2$  are independently  $\text{H}_2$ ,  $=\text{NR}^4$ ,  $=\text{O}$ , or a combination of H and  $-\text{NR}^5\text{R}^6$ ;

$\text{R}^1$  at  $\text{X}^2$  is a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, or an acyl including a C1 to C30 alkyl or an aromatic or heteroaromatic ring;

$\text{R}^1$  at  $\text{X}^3$  is hydrogen, a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, or an acyl including a C1 to C30 alkyl or an aromatic or heteroaromatic ring; and

$\text{R}^2$ ,  $\text{R}^4$ ,  $\text{R}^5$ , and  $\text{R}^6$  are independently hydrogen, a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, an acyl including a C1 to C30 alkyl or aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain C1 to C30 alkyl, or an aryloxyalkyl including straight or branched-chain C1 to C30 alkyl;

wherein when  $\text{R}^2$  at  $\text{X}^2$  is H and  $\text{Q}^2$  is  $=\text{O}$ ,  $\text{R}^1$  is a straight chain C10 to C18 alkyl group.

2. (canceled)
3. (previously presented) The compound according to claim 1, wherein the compound is from group (ii) and wherein
  - Q<sup>1</sup> is H<sub>2</sub>;
  - Q<sup>2</sup> is =O;
  - Z<sup>1</sup> is O; and
  - R<sup>2</sup> at both X<sup>2</sup> and X<sup>3</sup> is H.
4. (previously presented) The compound according to claim 3, wherein X<sup>3</sup> is —NH<sub>2</sub> and R<sup>1</sup> at X<sup>2</sup> is a straight chain C14 to C18 alkyl.
5. (previously presented) The compound according to claim 4, wherein R<sup>1</sup> at X<sup>2</sup> is a C14 alkyl.
6. (previously presented) The compound according to claim 4, wherein R<sup>1</sup> is at X<sup>2</sup> a C18 alkyl.
7. (previously presented) The compound according to claim 3, wherein
  - R<sup>1</sup> at X<sup>3</sup> is an acetyl group and
  - R<sup>1</sup> at X<sup>2</sup> is a C14 alkyl.
- 8-11 (canceled)
12. (original) A pharmaceutical composition comprising:
  - a pharmaceutically-acceptable carrier and
  - a compound according to claim 1.
- 13-34 (canceled)